Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107230 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL87921 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL22216666 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL1828721 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL728754 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL24782761 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21422636 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057384 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL21057351 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 | |
| SCHEMBL11147768 | 1.00 | HTR6 (0.54) | HTR6PHGDHMGLLL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1707 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4308096-B1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4211119-B1 | 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-03-10 | — | — | US | claimed |
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | claimed |
| EP-4665330-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-11-20 | — | — | US | claimed |
| EP-4644382-A1 | COMPOUND BASED ON SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE-BASED ISOINDOLINONE SKELETON AND USE THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2025-11-05 | — | — | EP | claimed |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-09-02 | — | — | US | claimed |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | COILED THERAPEUTICS, INC. | 2025-06-26 | — | — | US | claimed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | claimed |
| EP-0686629-A2 | Cyclohexyl tachykinine receptor antagonists | ELI LILLY AND COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| WO-1995014017-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-05-26 | — | — | WO | claimed |
| EP-0306861-B1 | STABILISATION OF CHLOROFLUOROALKANES | Kali-Chemie Aktiengesellschaft (DE) | 1992-12-30 | — | — | EP | claimed |
| US-4883913-A | BUT-3-EN-1-OL COMPOUNDS, MIXTURES OF CATALYSTS AND BLOWING AGENTS FOR POLYURETHANES | KALI-CHEMIE AKTIENGESELLSCHAFT (DE) | 1989-11-28 | — | — | US | claimed |
| US-4876269-A | ANALGESICS, DIURETICS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-10-24 | — | — | US | claimed |
| EP-0306861-A2 | Stabilisation of chlorofluoroalkanes | Kali-Chemie Aktiengesellschaft (DE) | 1989-03-15 | — | — | EP | claimed |
| US-4560767-A | N-(2-amino-cycloalkenyl)benzeneacetamide and -benzamide analgesics and tritiated kappa agonists therefrom | THE UPJOHN COMPANY (US) | 1985-12-24 | — | — | US | claimed |
| US-3996505-A | Capacitor with liquid polybutene dielectric | MCGRAW-EDISON COMPANY (US) | 1976-12-07 | — | — | US | claimed |
| US-3979308-A | MINERAL OIL AND AN AMINE PHOSPHATE | TEXACO INC. (US) | 1976-09-07 | — | — | US | claimed |
| US-3932539-A | Process for preparing unsaturated terpene alcohols | SCM CORPORATION (US) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570640-B2 | 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, CLK2 | HTR6 478/4885PHGDH 3963/4885MGLL 3257/4885 |
| US-20250353862-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | HTR6 4090/4885PHGDH 3169/4885MGLL 4487/4885 |
| US-20250206728-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NTPCR, PTPRC, NFATC1 | HTR6 3732/4885PHGDH 2116/4885MGLL 2250/4885 |
| US-12404283-B2 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | HTR6 4090/4885PHGDH 3169/4885MGLL 4487/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | HTR6 4311/4885PHGDH 942/4885MGLL 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.